FDA advisory committee backs Shire’s prucalopride
Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation.
Read More
Tag: 5-HT4 receptor agonist
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
- Oxford Drug Design reports major in vivo milestone for novel cancer therapy
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
